Preoperative serum carbohydrate antigen 19-9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma

Abstract

BACKGROUND

Pancreatic ductal adenocarcinoma (PDAC) is a serious disease with a poor prognosis. Only a minority of patients undergo surgery due to the advanced stage of the disease, and patients with early-stage disease, who are expected to have a better prognosis, often experience recurrence. Thus, it is important to identify the risk factors for early recurrence and to develop an adequate treatment plan.

AIM

To evaluate the predictive factors associated with the early recurrence of early-stage PDAC.

METHODS

This study enrolled 407 patients with stage I PDAC undergoing upfront surgical resection between January 2000 and April 2016. Early recurrence was defined as a diagnosis of recurrence within 6 mo of surgery. The optimal cutoff values were determined by receiver operating characteristic (ROC) analyses. Univariate and multivariate analyses were performed to identify the risk factors for early recurrence.

RESULTS

Of the 407 patients, 98 patients (24.1%) experienced early disease recurrence: 26 (26.5%) local and 72 (73.5%) distant sites. In total, 253 (62.2%) patients received adjuvant chemotherapy. On ROC curve analysis, the optimal cutoff values for early recurrence were 70 U/mL and 2.85 cm for carbohydrate antigen 19-9 (CA 19-9) levels and tumor size, respectively. Of the 181 patients with CA 19-9 level > 70 U/mL, 59 (32.6%) had early recurrence, compared to 39 (17.4%) of 226 patients with CA 19-9 level ≤ 70 U/mL (P < 0.001). Multivariate analysis revealed that CA 19-9 level > 70 U/mL (P = 0.006), tumor size > 2.85 cm (P = 0.004), poor differentiation (P = 0.008), and non-adjuvant chemotherapy (P = 0.025) were significant risk factors for early recurrence in early-stage PDAC.

CONCLUSION

Elevated CA 19-9 level (cutoff value > 70 U/mL) can be a reliable predictive factor for early recurrence in early-stage PDAC. As adjuvant chemotherapy can prevent early recurrence, it should be recommended for patients susceptible to early recurrence.

Key Words: Pancreatic ductal adenocarcinoma; Early recurrence; Upfront surgery; Carbohydrate antigen 19-9; Adjuvant chemotherapy

Core Tip: Pancreatic ductal adenocarcinoma (PDAC) is a serious disease with a poor prognosis. Only a minority of patients undergo surgery due to the advanced stage of the disease, and recurrence, an important prognostic factor, often occurs even after surgical resection. We identified the factors associated with the early recurrence of early-stage PDAC evaluating 407 patients with stage I PDAC undergoing upfront surgical resection. Early recurrence was defined as disease recurrence within 6 mo of surgery. Preoperative carbohydrate antigen 19-9 level > 70 U/mL determined by receiver operating characteristic analyses was a significant risk factor for early recurrence in early-stage PDAC.

INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) is a serious disease with a poor prognosis, with a 5-year survival rate of only 6%-10%[1,2]. While surgical resection offers the only possibility of cure[3], only a minority of patients are diagnosed with resectable disease because of local advancement or metastases at initial presentation[4]. Furthermore, even if patients undergo surgical treatment, about 70% experience disease recurrence[5-7]. Thus, efforts have been made to improve prognosis by early detection of the disease. However, even if patients are diagnosed and undergo surgery in the early stages, recurrence often occurs, and early recurrence is an important factor associated with a poor prognosis[8-10]. Therefore, it is necessary to identify the factors associated with the early recurrence of early-stage PDAC.

Various factors associated with PDAC prognosis have been reported including tumor size, preoperative carbohydrate antigen 19-9 (CA 19-9) concentration, histological grade, resection margin status, lymph node metastasis, and vascular invasion[11,12]. Among them, CA 19-9 levels, histological grade, and microvascular invasion are also associated with early recurrence[9,13-15]. Especially, serum CA 19-9 level, the only parameter that can be evaluated before surgery, has been regarded as a means of diagnosing malignant pancreatic neoplasms with high sensitivity and specificity[16,17]. Previous studies have also shown that CA 19-9 levels are a predictive factor for poor prognosis[18-22]. Elevated serum CA 19-9 levels are suggestive of pancreatic cancer recurrence, and serum CA 19-9 measurement is usually performed during surveillance, along with imaging tests, to detect cancer progression. Although imaging tests are performed to confirm cancer recurrence, CA 19-9 measurement is easier and more reproducible in terms of surveillance.

To improve the prognosis of pancreatic cancer, the risk factors for early recurrence should be evaluated, and active treatment, such as surgical treatment followed by chemotherapy, should be performed. Furthermore, as patients with early-stage disease, who are expected to have a better prognosis, often experience early recurrence, it is important to identify the risk factors for early recurrence and develop an adequate treatment plan. Pre- and post-operative CA 19-9 levels have been used to predict disease progression; however, few studies have demonstrated the effectiveness of CA 19-9 as a marker for early recurrence. This study evaluated the risk factors for early recurrence in patients with American Joint Committee on Cancer (AJCC) 8^th edition stage I PDAC after upfront surgery. We set the optimal cutoff CA 19-9 level and evaluated the power of CA 19-9 as a detector of early recurrence of early-stage PDAC. We also evaluated the importance of adjuvant chemotherapy as a therapeutic modality for early-stage patients to reduce the chance of early recurrence.

MATERIALS AND METHODS

Between January 2000 and April 2016, 2029 consecutive patients underwent surgical resection for PDAC at Asan Medical Center (Seoul, South Korea). PDAC was histologically confirmed in all patients, and patients with other pancreatic tumors such as intraductal papillary mucinous adenocarcinoma, adenosquamous carcinoma, mucinous carcinoma, acinar cell carcinoma, and malignant endocrine carcinoma were excluded. Of these, 648 patients had tumor-node-metastasis (TNM) stage IA and IB disease based on permanent pathologic reports. Forty-eight patients who received neoadjuvant chemotherapy, forty-four who were lost to follow-up, and five with incomplete data on preoperative serum CA 19-9 levels were excluded. Patients whose CA 19-9 levels were measured when they had jaundice (preoperative total bilirubin levels ≥ 2 mg/dL) were excluded to avoid the effect of obstructive jaundice on CA 19-9 values. Patients with preoperative CA 19-9 level < 2 U/mL were considered as Lewis antibody-negative patients; thus, they were considered to be unable to express CA 19-9 and were excluded from this study. Finally, 407 patients who underwent upfront surgical resection for stage I PDAC were enrolled in this study (Figure 1). Data regarding age, sex, body mass index, type of operation, pathology, recurrence, and preoperative serum CA 19-9 levels were obtained retrospectively from medical records. All patients underwent either abdominal computed tomography (CT), magnetic resonance imaging, or both preoperatively for the evaluation of tumor lesion and resectability. The pathologic stage was determined according to the TNM Classification of Malignant Tumors, 8th edition, from the AJCC.

Figure 1 Flowchart of patient selection. CA 19-9: Carbohydrate antigen 19-9; PDAC: Pancreatic ductal adenocarcinoma; TNM: Tumor-node-metastasis.

All serum CA 19-9 values were measured using an electrochemiluminescence immunoassay kit in the institution’s laboratory. The recommended upper normal limit for CA 19-9 is 37 U/mL. CA 19-9 levels were examined within 1 mo before the surgery. When patients developed jaundice due to tumor invasion of the biliary tract, interventions were performed, including endoscopic nasobiliary drainage, endoscopic retrograde biliary drainage, or percutaneous transhepatic biliary drainage.

Distal pancreatectomy was the standard procedure for tumors of the pancreatic neck, body, or tail. Pancreaticoduodenectomy (pylorus-preserving or pylorus-resecting) was performed for tumors located in the pancreas head or uncinate. Total pancreatectomy was performed in patients in whom intra-operative frozen biopsy showed positive resection margin, remnant pancreas was atrophied, pancreatitis was very severe involving the whole pancreas, and pancreatic duct was dilated throughout the pancreas. The surgeries were performed using either an open approach or laparoscopically. The pathologic characteristics included tumor size, resection margin status, lymph node metastasis, differentiation, lymphovascular invasion, and perineural invasion status. The resection margins were evaluated by a pathologist as either R0 (no cancer cells observed microscopically at the resection margin) or R1 (cancer cells observed microscopically at the resection margin or a free margin of < 1 mm).

The patients were followed up with abdominal CT and blood tests, including tests for tumor markers, CA 19-9, and carcinoembryonic antigen levels, every 3 mo for the first 2 years after surgery and every 3-6 mo thereafter. When the CA 19-9 level was elevated or abdominal CT suggested tumor recurrence, additional positron emission tomography (PET) was performed. Tumor recurrence was defined based on radiological or biopsy-proven evidence. Radiological recurrence was determined by radiologists and defined as progressive soft-tissue growth or hypermetabolic lesions at specific sites, as determined by CT or PET. Biopsy was not routinely required for the diagnosis of tumor recurrence.

Overall survival (OS) was defined as the time from surgery to the date of death from any cause or the last follow-up visit. Disease-free survival (DFS) was defined as the time from surgery to the first documented detection of recurrence on CT or PET during regular follow-up or death, whichever occurred first. Early recurrence was defined as disease relapse within 6 mo of surgery.

Statistical analyses

Continuous variables are expressed as medians and interquartile ranges. OS and DFS were estimated using the Kaplan–Meier method, and the values were compared using log-rank tests. Receiver operating characteristic (ROC) curves were constructed to estimate the optimal cutoff values for preoperative CA 19-9 levels and tumor size as predictors of postoperative early recurrence, with the Youden index used as a summary measure of the ROC curve. The χ² or Fisher’s exact test was performed for categorical variables. Univariate and multivariate analyses were performed using a logistic regression model to determine the predictive variables associated with early recurrence. P < 0.05 was considered statistically significant. The statistical analyses were performed using IBM SPSS Statistics for Windows, version 22.0 (IBM Corp., Armonk, NY, United States).

RESULTS

Patient’s characteristics

This study included 407 patients. Of them, 225 (55.3%) were male and 182 (44.7%) were female, with a median age of 62 years (30-88). The median follow-up time was 31 mo (1-227). A total of 254 patients (62.4%) underwent pancreatectomy for tumors located at the head or uncinate, and 151 (37.1%) underwent pancreatectomy for tumors located at the pancreatic neck, body, or tail. Permanent biopsy result revealed that the tumor involved both head and body in two cases (0.5%). The median tumor size was 2.5 cm (0.3-4), and the median number of harvested lymph nodes was 14. A total of 253 patients (62.2%) received adjuvant chemotherapy. The median OS durations in the early and non-early recurrence groups were 11 and 42 mo, respectively (P < 0.001). The demographic and pathologic findings are summarized in Table 1.

Table 1 Patient demographics.

Characteristics	Patients, n = 407 (%)
Age in yr, median (range)	62 (30-88)
Sex, n (%)
Male	225 (55.3)
Female	182 (44.7)
BMI in kg/m2, median (range)	23.2 (15.3-31.6)
Pre-op CA 19-9 in U/mL, n (%)
Normal	167 (41)
Abnormal	240 (59)
Tumor location, n (%)
Head/uncinate	254 (62.4)
Neck/body/tail	151 (37.1)
Head/body	2 (0.5)
Tumor size, median, cm (range)	2.5 (0.3-4.0)
Total number of harvested lymph nodes, median (range)	14 (1-74)
Differentiation, n (%)
Well	60 (14.9)
Poor	288 (71.6)
Unknown	54 (13.4)
Moderate	5 (1.2)
Stage, n (%)
IA	109 (26.8)
IB	298 (73.2)
Adjuvant chemotherapy, n (%)
No	154 (37.8)
Yes	253 (62.2)
Recurrence within 6 mo, n (%)
No	309 (75.9)
Yes	98 (24.1)

BMI: Body mass index; CA 19-9: Carbohydrate antigen 19-9.

The median follow-up duration was 31 mo. A total of 304 patients (75.4%) showed disease recurrence, with a median time to recurrence of 10 mo. In this study, 99 (32.6%) and 205 (67.4%) patients had local and distant recurrences, respectively. Among the patients with distant recurrence, the most common recurrence site was the liver, followed by peritoneal seeding and the lungs. A total of 98 patients (24.1%) had early recurrence, and 309 (75.9%) had either non-early or no recurrence. Among patients with early recurrence, 26 (26.5%) had local recurrence and 72 (73.5%) had distant recurrence. The most common recurrence site was the liver (37.8%).

Preoperative serum CA 19-9 and early recurrence

ROC curve analysis revealed 70 U/mL as the optimal cutoff preoperative CA 19-9 level for predicting early recurrence (area under the curve [AUC] 0.605; sensitivity 60.2%, specificity 60.5%; Figure 2A). In this study, 181 patients had preoperative serum CA 19-9 level ≥ 70 U/mL; among them, 59 patients (32.6%) had early recurrence. In contrast, 39 of the 226 patients (17.4%) with CA 19-9 level < 70 U/mL had early recurrence (P < 0.001). We had postoperative serum CA 19-9 values checked within 1 mo after the operation. Among the 181 patients with preoperative serum CA 19-9 values ≥ 70 U/mL, 171 patients (94%) had decreased serum CA 19-9 values after the operation, and of these, 49 patients (28.7%) experienced early disease recurrence. Nine patients had rather increased serum CA 19-9 value, and all of these patients experienced early recurrence. In one patient, we did not check the postoperative CA 19-9 value. ROC curve analysis also revealed 2.85 cm as the optimal cutoff tumor size for predicting early recurrence (AUC 0.619; sensitivity 56.1%, specificity 65.0%; Figure 2B).

Figure 2 Receiver operating characteristic curve of serum carbohydrate antigen 19-9. A: Receiver operating characteristic (ROC) curve for carbohydrate antigen 19-9 (CA 19-9) values and early recurrence in tumor-node-metastasis (TNM) stage I patients who underwent pancreatic resection; B: ROC curve for tumor size and early recurrence in TNM stage I patients who underwent pancreatic resection. AUC: Area under the curve.

Multivariate analysis on risk factors for early recurrence

Table 2 shows the risk factors associated with early recurrence after curative surgical resection for TNM stage I PDAC. In the univariate analysis, preoperative serum CA 19-9 level (P < 0.001), tumor size (P < 0.001), and differentiation (P = 0.005) were significant. In the multivariate analysis, a CA 19-9 level ≥ 70 U/mL (odds ratio [OR] 1.987; P = 0.006), tumor size ≥ 2.85 cm (OR 2.039; P = 0.004), poor differentiation (OR 3.493 for poorly differentiated vs well differentiated; P = 0.008), and non-adjuvant chemotherapy (OR 1.745; P = 0.025) were significantly associated with early recurrence after surgical resection.

Table 2 Univariate and multivariate analyses of the factors associated with early recurrence.

Factors	Number of patients, n (%)	Univariate, P value	Odds ratio (95%CI)	Multivariate, P value
Age in yr		0.211	`
< 65	234 (57.5)
≥ 65	173 (42.5)
Sex		0.261
Male	225 (55.3)
Female	182 (44.7)
Tumor size in cm		< 0.001		0.004
< 2.85	244 (60.0)
≥ 2.85	163 (40.0)		2.039 (1.251-3.323)
RM		0.555		0.638
Negative	348 (85.5)
Positive	59 (14.5)		1.177 (0.583-2.287)
Tumor location		0.394
Head/uncinate	254 (62.4)
Neck/body/tail	151 (37.1)
Differentiation		0.005		0.019
Well	60 (14.9)
Moderate	288 (71.6)	0.196	1.430 (0.652–3.133)	0.372
Poor	54 (13.4)	0.005	3.493 (1.377–8.858)	0.008
CA 19-9 in U/mL		< 0.001		0.006
< 70	226 (55.5)
≥ 70	181 (44.5)		1.987 (1.217–3.243)
LVi		0.126		0.372
No	263 (64.6)
Yes	144 (35.4)		1.270 (0.749–2.144)
PNi		0.517		0.911
No	110 (27.0)
Yes	297 (73.0)		0.966 (0.535–1.780)
NLR		0.768
< 2	244 (60.0)
≥ 2	163 (40.0)
Adj. CTx.		0.059		0.025
No	154 (37.8)
Yes	253 (62.2)		0.573 (0.352–0.933)

Adj. CTx.: Adjuvant chemotherapy; CA 19-9: Carbohydrate antigen 19-9; CI: Confidence interval; LVi: Lymphovascular invasion; NLR; Neutrophil-lymphocyte ratio; PNi; Perineural invasion; RM: Resection margin.

Early recurrence vs non-early recurrence

Table 3 shows the comparisons between the early and non-early recurrence groups. Of the 407 patients, 98 (24.1%) had early disease recurrence and 309 (75.9%) had non-early or no recurrence. The preoperative CA 19-9 level significantly differed between the groups (P = 0.004), with higher CA 19-9 levels prevalent among patients in the early recurrence group. Tumors in the early recurrence group were larger (P = 0.001) and showed a more poorly differentiated histology (P = 0.002) than those in the non-early recurrence group. Although the difference was not significant (P = 0.058), more patients in the non-early recurrence group received adjuvant chemotherapy. The recurrence pattern did not differ between the two groups.

Table 3 Comparisons between the early and non-early recurrence group.

Factors	Early recurrence, n (%)	Non-early recurrence, n (%)	P value
	N = 98 (24.1%)	N = 309 (75.9%)
Age in yr			0.21
<65	51 (52.0)	183 (59.2)
≥ 65	47 (48.0)	126 (40.8)
Sex			0.261
Male	59 (60.2)	166 (53.7)
Female	39 (39.8)	143 (46.3)
Tumor size, median in cm			0.001
< 2.5	23 (23.5)	129 (41.7)
≥ 2.5	75 (76.5)	180 (58.3)
RM			0.555
Negative	82 (83.7)	266 (86.1)
Positive	16 (16.3)	43 (13.9)
Tumor location			0.712
Head/uncinate	63 (64.3)	191 (62.2)
Neck/body/tail	35 (35.7)	116 (37.8)
Differentiation			0.002
Well	9 (9.2)	51 (16.5)
Moderate	65 (66.3)	223 (72.2)
Poor	22 (22.4)	32 (10.4)
Preoperative CA 19-9 in U/mL			0.004
Normal	28 (28.6)	139 (45.0)
Abnormal	70 (71.4)	170 (55.0)
LVi			0.125
No	57 (58.2)	206 (66.7)
Yes	41 (41.8)	103 (33.3)
PNi			0.516
No	24 (24.5)	86 (27.8)
Yes	74 (75.5)	223 (72.2)
NLR			0.768
< 2	60 (61.2)	184 (59.5)
≥ 2	38 (38.8)	125 (40.5)
Adj. CTx.			0.058
No	45 (45.9)	109 (35.3)
Yes	53 (54.1)	200 (64.7)
Recurrence pattern			0.121
Local	26 (26.5)	73 (35.4)
Systemic	72 (73.5)	133 (64.6)

Adj. CTx.: Adjuvant chemotherapy; CA 19-9: Carbohydrate antigen 19-9; LVi: Lymphovascular invasion; N: Total number of patients; NLR: Neutrophil-lymphocyte ratio; PNi: Perineural invasion; RM: Resection margin.

DISCUSSION

PDAC is one of the most lethal malignancies and is a leading cause of cancer-related deaths worldwide. Despite substantial improvements in the survival rates of patients with other major malignancies, the survival rates of patients with PDAC have remained relatively unchanged. PDAC is usually detected in the advanced stage, and restricted treatment options contribute to its poor overall prognosis. Approximately 70%-80% of patients with PDAC experience locoregional and/or distant recurrence after surgery[5-7]. Recent efforts have sought to improve the early diagnosis of PDAC[23-27]. Early detection and treatment of PDAC can help improve the dismal prognosis of this aggressive cancer. We evaluated the OS of 407 early-stage (stage I) PDAC patients who underwent upfront pancreatic surgery between January 2000 and April 2016. The median OS of those with early-stage disease was 34.5 mo, significantly longer than that of those with advanced-stage disease (18.5 mo; P < 0.001). However, patients with early-stage PDAC often experience early recurrence after curative resection, leading to a poor prognosis. The results of the present study suggested the presence of a heterogeneous microenvironment in terms of pre-existing occult metastasis in early-stage PDAC as 24.1% (n = 98) of patients with early recurrence showed a relatively poor prognosis compared to that in the non-early recurrence group (75.9%, n = 309) (median OS: 11 vs 42 mo; P < 0.001). Therefore, it is important to identify the clinicopathological factors and therapeutic modalities that are significantly associated with early recurrence in early-stage PDAC to improve the prognosis of this dismal disease.

Several studies have reported risk factors associated with OS and recurrence after surgical resection for PDAC, including tumor size, histological grade, resection margin status, lymph node metastasis, perineural invasion, venous invasion, and preoperative CA 19-9 levels[6,28-31]. The results of our study suggested that high preoperative serum CA 19-9 levels, large tumor size, poor differentiation, and non-adjuvant chemotherapy were independent predictors of early recurrence in early-stage PDAC.

Tumor size is an independent predictor of poor prognosis in patients with PDAC[32-34]. Based on previous studies, we further evaluated the effect of tumor size on recurrence and survival in patients with early-stage PDAC treated with curative resection. The median DFS and OS were 10 mo and 23 mo, respectively, in the larger tumor group (≥ 2.85 cm) and 21 mo and 38 mo in the smaller tumor group (< 2.85 cm), demonstrating that tumor size was an independent clinical predictor for early recurrence in early-stage PDAC. Since tumor size, as expected, affected disease prognosis and early recurrence even in early-stage disease, scheduled surveillance for detecting early recurrence is necessary in early-stage patients with large tumors.

Tumor histological grade is an important independent prognostic factor for PDAC. In general, poorly differentiation reflects aggressive malignant behavior accompanying a larger tumor size, a high rate of nodal metastases, microvascular invasion, and perineural invasion, causing poor OS[35-38]. The results of this study demonstrated that poor tumor differentiation was a significant factor for early recurrence in early PDAC compared to well differentiation (P = 0.008). Tumor grade is associated with not only survival but also recurrence. Although tumor grade is not used to evaluate tumor stage in PDAC according to the AJCC 8^th edition guidelines, it should be considered critical for predicting disease prognosis and recurrence, especially in patients with early-stage PDAC.

CA 19-9, also referred to as Sialyl Lewis-A, is regularly expressed on cancer cells and can be detected by the monoclonal antibody 19-9[8]. Although it was originally isolated from a human colorectal cancer cell line[39], CA 19-9 is a good marker for the diagnosis of PDAC and the detection of recurrence during routine surveillance. It can be easily evaluated by a simple blood test, and numerous reports have suggested CA 19-9 as a meaningful tumor marker not only for diagnosis but also for prognosis prediction[18]. However, the specific role of CA 19-9 and the optimal serum CA 19-9 cutoff values for predicting early PDAC recurrence have remained controversial. We focused on early-stage PDAC patients who underwent primary pancreatectomy to evaluate the clinical impact of preoperative serum CA 19-9 levels on early recurrence. To the best of our knowledge, this is the first study to identify the independent relationship between serum CA 19-9 levels and early recurrence of early-stage PDAC in a large number of patients. In this study, we demonstrated that an elevated CA 19-9 level (cutoff value: > 70 U/mL) can be a reliable predictive marker for early recurrence in early-stage PDAC. This finding supports the notion that preoperative serum CA 19-9 levels could reflect biological aggressiveness and the presence of tumor micrometastases in early-stage PDAC.

Adjuvant chemotherapy was introduced following the assessment of its benefits, in which 5-fluorouracil (5-FU) and gemcitabine (GEM)-based regimens showed a survival effect[40,41]. The CONKO-005 trial also demonstrated that adjuvant chemotherapy with GEM and capecitabine doubled the 5-year OS rate to approximately 30%-50% compared to mono-regimen chemotherapy[42]. Adjuvant chemotherapy improved not only OS but also DFS[43,44]. In our institution, adjuvant chemotherapy is recommended to basically all patients regardless of the disease stage. However, the final decision is made based on the oncologists’ decision and patients’ postoperative general condition. In our study, patients who were in poor general condition, with postoperative complication, old, or reluctant to chemotherapy did not undergo adjuvant chemotherapy. Otherwise, 5-FU or GEM-based regimens were generally administered. We found that the number of patients who received adjuvant chemotherapy was higher in the late- and non-recurrence groups than in the early recurrence group (n = 200 vs 53), with adjuvant chemotherapy being an independent predictor of early recurrence (OR 0.573 [0.352–0.933]; P = 0.025) in early-stage PDAC. As few studies have assessed the effect of chemotherapy in early-stage disease, this result is meaningful in that we focused on early-stage patients. Adjuvant chemotherapy could be an effective treatment modality for reducing recurrence rates even in early-stage patients.

CONCLUSION

In conclusion, early recurrence often occurs even in stage I PDAC patients after upfront surgery, suggesting the need for the evaluation of predictive factors for early recurrence. In particular, CA 19-9 levels can be easily checked preoperatively and elevated CA 19-9 level (cutoff value > 70 U/mL) can be a reliable predictive factor. Furthermore, adjuvant chemotherapy should be considered for patients who are susceptible to early recurrence to achieve a better prognosis, even in patients with early-stage PDAC.

ARTICLE HIGHLIGHTS

Research background

One of the reasons that pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis is that the disease is diagnosed at advanced stage. Various factors associated with PDAC prognosis have been evaluated and effort have been made to improve prognosis by early detection of the disease.

Research motivation

Serum carbohydrate antigen 19-9 (CA 19-9) has been used as a means of diagnosing malignant pancreatic neoplasm and detection of disease recurrence. However, the effectiveness of CA 19-9 as a marker for early recurrence of disease has not been well studied yet.

Research objectives

This study aimed to set the optimal cutoff preoperative CA 19-9 level and evaluate the effectiveness of CA 19-9 as a detector of early recurrence of early-stage PDAC.

Research methods

A total of 407 patients with stage I PDAC undergoing upfront surgical resection between January 2000 and April 2016 were evaluated. The optimal cutoff values were determined by receiver operating characteristic and the risk factors for early recurrence were identified using a logistic regression model.

Research results

Ninety-eight patients (24.1%) experienced early disease recurrence. The optimal cutoff value of preoperative CA 19-9 for early recurrence was determined as 70 U/mL. Patients with high CA 19-9 level showed the tendency to have early recurrence more frequently. Tumor size > 2.85 cm, poor differentiation, and non-adjuvant chemotherapy were also demonstrated to be significant risk factors for early recurrence in early-stage PDAC.

Research conclusions

Elevated CA 19-9 level can be regarded as a reliable parameter predicting early disease recurrence. Adjuvant chemotherapy should be recommended for patients susceptible to early recurrence.

Research perspectives

Preoperative CA 19-9 can be a guidance for patients to undergo effective treatment modality to reduce early recurrence, thus leading to a better prognosis.